First Trust Advisors LP Buys 1,126,069 Shares of Genmab A/S Sponsored ADR $GMAB

First Trust Advisors LP boosted its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 84.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,461,342 shares of the company’s stock after acquiring an additional 1,126,069 shares during the period. First Trust Advisors LP’s holdings in Genmab A/S were worth $66,038,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. CIBC Private Wealth Group LLC lifted its stake in Genmab A/S by 291.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after purchasing an additional 616 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares during the last quarter. V Square Quantitative Management LLC purchased a new position in shares of Genmab A/S during the first quarter valued at about $34,000. NewEdge Advisors LLC grew its position in shares of Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after purchasing an additional 1,143 shares in the last quarter. Finally, Brown Brothers Harriman & Co. increased its holdings in shares of Genmab A/S by 143.4% in the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Stock Down 1.0%

Shares of NASDAQ GMAB opened at $28.87 on Friday. The firm’s 50-day moving average price is $26.82 and its 200-day moving average price is $28.32. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. The stock has a market capitalization of $18.00 billion, a price-to-earnings ratio of 21.87, a P/E/G ratio of 1.83 and a beta of 0.84. Genmab A/S Sponsored ADR has a 12-month low of $21.00 and a 12-month high of $35.43.

Analyst Ratings Changes

A number of equities research analysts recently commented on GMAB shares. Truist Financial initiated coverage on Genmab A/S in a research report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 target price on the stock. The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. New Street Research set a $43.00 price objective on Genmab A/S in a report on Wednesday. TD Cowen upgraded Genmab A/S from a “hold” rating to a “buy” rating and increased their target price for the company from $32.00 to $43.00 in a research report on Wednesday. Finally, BNP Paribas Exane raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus price target of $39.28.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.